Invokana FDA Approval History
Reviewed by J.Stewart BPharm. Last updated on Sep 30, 2019.
FDA Approved: Yes (First approved March 29, 2013)
Brand name: Invokana
Generic name: canagliflozin
Dosage form: Tablets
Company: Janssen Research & Development, LLC
Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction, Diabetic Kidney Disease
Invokana (canagliflozin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor indicated:
- along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes
- to reduce the risk of major cardiovascular events in adults with type 2 diabetes who have known cardiovascular disease
- to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine.
Development Timeline for Invokana
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.